

SEQUENCE LISTING

CIP E
AUG 19 2003
PARENTAL TRACE
10> PERLAN THERAPEUTICS
FANG, FANG

<150> MULTIVALENT RECOMBINANT ANTIBODIES FOR TREATING HRV INFECTIONS

<130> 014357-0278749

<140> 09/555,446
<141> 2000-08-16

<150> PCT/US98/25422
<151> 1998-11-30

<150> US 60/067,119
<151> 1997-12-01

<150> US 60/083,046
<151> 1998-04-24

<150> US 60/090,632
<151> 1998-06-25

<160> 15

<170> PatentIn Ver. 3.1

<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human
peptide residues

<400> 1
Gln Thr Ser Val Ser
1 5

<210> 2
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human
peptide residues

<400> 2
Ser Cys Asp Gln Pro Lys
1 5

<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human
peptide residues

<400> 3
Lys Glu Leu Leu Pro Gly Asn Asn Arg
1 5 10

<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human
peptide residues

<400> 4
Pro Asp Gly Gln Ser Thr Ala Lys
1 5

<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: linker sequence

<400> 5
Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
1 5 10 15

<210> 6
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: hinge region sequence

<400> 6
Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln Pro Lys
1 5 10 15

Pro Gln Pro Lys Pro Glu Pro Glu
20

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human complementary peptide sequence

<400> 7
Val Cys Arg His Arg 5
1

<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human complementary peptide sequence

<400> 8
Gly His Arg Cys Leu 5
1

<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human complementary peptide sequence

<400> 9
Leu Gly Leu Val Thr Gly 5
1

<210> 10
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human complementary peptide sequence

<400> 10
Arg Thr Leu Val Gly Phe 5
1

<210> 11
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human complementary
peptide sequence

<400> 11
Pro Val Val Pro Arg Gln Glu Gln Leu Leu
1 5 10

<210> 12
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human complementary
peptide sequence

<400> 12
Phe Leu Asn Glu Asp Gly Pro Leu Leu Ala
1 5 10

<210> 13
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human complementary
peptide sequence

<400> 13
Phe Ser Cys Ser Leu Pro Ile Arg
1 5

<210> 14
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: human complementary
peptide sequence

<400> 14
Gly Ile Pro Val Ser Cys Arg Phe
1 5

<210> 15

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer sequence

<400> 15
ccctcatagt taagcgtaac g

21